Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

@article{deRossi2020EarlyUO,
  title={Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up},
  author={Nicola de Rossi and Cristina Scarpazza and Chiara Filippini and Cinzia Cordioli and Sarah Rasia and Chiara Rosa Mancinelli and Damiano Rizzoni and Giuseppe Romanelli and Stefania Cossi and Nereo Vettoretto and Sergio Bove and Silvano Manfredini and Eva Andrea Beindorf and C Mosca and V. Scipione and G. Flamminio and Elena Albini and Paola Giansiracusa and Ruggero Capra},
  journal={EClinicalMedicine},
  year={2020},
  volume={25}
}
Abstract Background Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19… 
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
TLDR
Tocilizumab was a safe and efficacious therapeutic option for patients with moderate-to-severe COVID-19 pneumonia and its efficacy was improved by the concomitant administration of corticosteroids in patients affected by severe-COVID- 19 pneumonia at baseline.
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial
TLDR
Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure.
Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India
TLDR
Patients of severe COVID-19 pneumonia with persistent hypoxia who were admitted to a tertiary care center in Mumbai, India, between 31st March to 5th July 2020 were studied and median survival in the tocilizumab group was significantly longer than in the control group.
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study
TLDR
Evidence is provided to support a fixed dose of tocilizumab 600 mg in COVID-19 patients, a safe, logistically attractive, and drug expenses saving alternative compared with the current 8 mg/kg recommendation.
Tocilizumab administration for the treatment of hospitalized patients with COVID‐19: A systematic review and meta‐analysis
TLDR
Tocilizumab was associated with lower mortality and other clinically relevant outcomes in hospitalized patients with moderate‐to‐critical COVID‐19, and both RCTs and observational studies showed a benefit from tocilizumabs on the composite endpoint of mortality or IMV.
Fixed dosing of tocilizumab in ICU admitted COVID-19 patients is a superior choice compared to bodyweight based dosing; an observational population pharmacokinetic and pharmacodynamic study
TLDR
This study provides evidence to support a fixed dose of 600 mg tocilizumab in COVID-19 patients and suggests that alternative cost saving regimens with even lower doses are likely to be as effective as the current 8 mg/kg recommendation.
Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study
TLDR
It is demonstrated that some co-morbidities and cardiovascular risk factors may affect prognosis in patients with COVID-19 and the radiologic Brixia score may be a useful tool to stratify the risk of death at baseline.
A single-center experience in use of tocilizumab in COVID-19 pneumonia in India
TLDR
Deliberate patient selection and timing initiation of TCZ at a crucial stage of the disease may be beneficial in COVID-19 pneumonia with good safety returns.
A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections
TLDR
Inhibition of IL-6 with tocilizumab and siltuximab requires further evaluation in managing the assumed hyperinflammatory response associated with severe Covid-19, and justify the need for well-designed randomised clinical studies.
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update
TLDR
A living systematic review of the literature concerning the efficacy and toxicity of the IL-6 receptor antagonist, tocilizumab, in COVID-19 patients and the certainty of evidence was assessed using the GRADE approach.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 55 REFERENCES
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
TLDR
Clinical improvement and mortality were not statistically significant different between tocilizumab and standard treatment patients in this retrospective study on severe COVID-19 patients with hyper-inflammatory features.
Clinical characteristics and early outcomes in patients with COVID-19 treated with tocilizumab at a United States academic center
TLDR
The findings suggest that tocilizumab should be used with caution in severe and critically ill patients and highlight the need for data from randomized controlled trials to determine its efficacy in the treatment of COVID-19.
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
TLDR
It was showed that COVID-19 pneumonia with ARDS was characterized by HIS, and the response to TCZ was rapid, sustained, and associated with significant clinical improvement.
Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
TLDR
Despite the small sample size and retrospective nature of the work, this result strongly suggests that TCZ may reduce the number of ICU admissions and/or mortality in patients with severe SARS-CoV-2 pneumonia.
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.
TLDR
In hospitalised adult patients with severe COVID-19, TCZ could be a safe option and an improvement in respiratory and laboratory parameters was observed, requiring future controlled trials to confirm the definite benefit with IL-6 target therapy.
Tocilizumab treatment in COVID‐19: A single center experience
TLDR
TCZ appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms and for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
TLDR
Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
TLDR
The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome.
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
TLDR
The unique pattern of immune dysregulation in severe COVID-19 is characterized by IL-6-mediated low HLA-DR expression and lymphopenia, associated with sustained cytokine production and hyper-inflammation.
Why tocilizumab could be an effective treatment for severe COVID-19?
TLDR
It is suggested that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.
...
1
2
3
4
5
...